Announced details
Treatment of chronic spinal cord injury; therapeutic approach aimed at restoring motor and bladder function
In the chronic phase of animal models of complete spinal cord injury, recovery of motor and bladder function was observed (specific figures: not disclosed)
Joint research and intellectual property relationship arising from the joint filing of a patent for a therapeutic agent for chronic spinal cord injury
Chairman: Ito Kohei (伊藤 公平). An educational foundation operating a university medical school, a regenerative medicine research center and other facilities. Location, capital and year established: not disclosed
Patent No. 7838207; validity period: not disclosed
Securing rights to this patent is expected to expand the pipeline in the spinal cord injury field. The specific impact on business performance: not disclosed
The company does not address Contract Value / Offering price.
Press release dated 1 February 2023 by the Keio University School of Medicine; Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Therapeutic agent for spinal cord injury; scaffold containing hepatocyte growth factor (HGF) |
| Counterparty | Keio Gijuku (Keio University) |
| Counterparty overview | Chairman: Ito Kohei (伊藤 公平). An educational foundation operating a university medical school, a regenerative medicine research center and other facilities. Location, capital and year established: not disclosed |
| Relationship with the Company | Joint research and intellectual property relationship arising from the joint filing of a patent for a therapeutic agent for chronic spinal cord injury |
| Applicable area | Treatment of chronic spinal cord injury; therapeutic approach aimed at restoring motor and bladder function |
| Registration number and expiry date | Patent No. 7838207; validity period: not disclosed |
| Quantitative Effects | In the chronic phase of animal models of complete spinal cord injury, recovery of motor and bladder function was observed (specific figures: not disclosed) |
| Impact on Business Performance | Securing rights to this patent is expected to expand the pipeline in the spinal cord injury field. The specific impact on business performance: not disclosed |
| Source | Press release dated 1 February 2023 by the Keio University School of Medicine; Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To secure intellectual property rights for a new therapeutic approach targeting chronic spinal cord injury and expand the pipeline in the spinal cord injury field.